To prove the efficacy of the exosome-based nanomedicine in a DLBCL-resistant tumor model, results indicated that aCD20@ExoCTX/siPDK4 effectively downregulated PDK4 gene expression in vivo, enhancing the antitumor activity of rituximab and thereby inhibiting the generation of DLBCL tumor cells. This evidence concerns the gene PDK4 and neoplasm.